Sun Pharmaceutical opened at ₹1,760.00, in line with its previous close of ₹1,760.00. During today's session, the stock has traded between ₹1,750.60 and ₹1,770.70, with an average traded price of ₹1,762.85. It is currently showing a sideways intraday trend.
An investment of ₹10,000 made 5 years ago in Sun Pharmaceutical is now worth
₹ 21,341.00
giving a profit of
₹ 11,341.00 (113.41%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
+10.70 (+0.61%)
Day High
₹1,770.70
Day Low
₹1,750.60
Day Open
₹1,760.00
Prev Close
₹1,760.00
Volume
11,91,057
Value Traded
₹209.97 Cr
1W Return
-0.51%
1M Return
-3.77%
3M Return
-8.51%
6M Return
7.00%
1Y Return
5.97%
Market Cap (₹ Cr.)
4,24,850
PE Ratio
34.80
PB Ratio
5.05
Dividend Yield
0.91%
ROE
13.79%
ROCE
17.94%
Book Value (₹)
348.31
Face Value (₹)
1.00
EPS (TTM)
12.10
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-0.51%
6 Week
-
1 Month
-3.77%
3 Month
-8.51%
9 Month
2.00%
Sun Pharma board to meet October 12 on NCD issue up to ₹15,000 crore
Sun Pharma board meets October 12, 2026. Proposes NCD issue up to ₹15,000 crore. Issuance via private placement basis. NCDs to be unsecured and rated.
6 days agoSun Pharma establishes $2.5 million dermatology professorship at Mount Sinai
Sun Pharma established a $2.5 million endowed professorship in dermatology at Mount Sinai. Mark G. Lebwohl installed as inaugural professor on October 6, 2026. Endowment supports research, education, and mentorship in perpetuity. Sun Pharma is second-largest U.S. dermatology pharma by prescription volume.
7 days agoSun Pharma seeks approval for ESOP 2026 and ₹700 billion borrowing limit
Sun Pharma proposes ESOP 2026 with 12 million options via secondary market acquisition, avoiding equity dilution. Borrowing limit enhancement sought from ₹500 billion to ₹700 billion to fund Organon acquisition. Investment and guarantee limits proposed to increase from ₹500 billion to ₹800 billion under Section 186. Approval sought to pledge Organon shares to secure up to $12 billion in acquisition financing facilities.
12 days agoSun Pharma reports sustained LEQSELVI efficacy in two-year alopecia study
Sun Pharma presented seven LEQSELVI studies at EADV Congress 2026. 93.9% of baseline responders maintained scalp hair regrowth at Week 108. 76.6% of baseline nonresponders achieved response by Week 52. Safety profile remained consistent with no major cardiovascular events reported. Data supports LEQSELVI as a long-term treatment option for severe alopecia areata.
12 days agoSun Pharma reports 15.86% drop in carbon emissions for FY26
Absolute Scope 1 and 2 carbon emissions reduced by 15.86% against the 2020 baseline. Female representation in the global workforce reached 17.97%, with 13.44% in top management. CSR spend totaled INR 2,068 million, impacting nearly 2.23 million lives in India. Renewable energy sources contributed 43% to total energy consumption during FY26. Board meeting attendance averaged 95.24%, with 50% independent directors on the board.
14 days agoSun Pharma shareholders approve reclassification of promoters to public
Shareholders approved reclassification of promoters to public category on Sept 26, 2026. Process completed via postal ballot initiated by notice dated Aug 25, 2026. Remote e-voting period ran from Aug 28 to Sept 26, 2026. Resolution passed under SEBI Regulation 31A of LODR Regulations, 2015.
15 days ago| Contract | Days to Expiry | LTP | Change | Change % | Volume | OI | OI Chg % |
|---|---|---|---|---|---|---|---|
| SUNPHARMA OCT FUT | 15 | 1,777.70 | 15.40 | 0.87 | 6,04,100 | 1,57,04,500 | 0.23 |
| SUNPHARMA NOV FUT | 42 | 1,782.50 | 10.40 | 0.59 | 73,500 | 12,48,800 | 4.30 |
| SUNPHARMA DEC FUT | 78 | 1,793.20 | 5.70 | 0.32 | 24,500 | 53,200 | 56.70 |
| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% | |
| ₹351.00 | +1.34% | ₹57,202.26 | 134.86 | -0.69% |
An investment of ₹10,000 made 5 years ago in Sun Pharmaceutical is now worth
₹ 21,341.00
giving a profit of
₹ 11,341.00 (113.41%)
Note: Past profits do not guarantee future returns.
